Amgen research cuts buck top pharma trend
This article was originally published in Scrip
Amgen has now confirmed that it is to reduce its research and development employees by some 380 positions. The number represents just over a 2% reduction in Amgen�s total workforce, but around 10% of those involved in R&D. However, those observers who have welcomed the cuts as a sign that Amgen is bringing its R&D commitments into line with pharma industry norms, may need to re-examine the industry-wide spending data.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.